Impact of structural changes in heteroleptic bismuth phosphinates on their antibacterial activity in Bi-nanocellulose composites

Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome

Bismuth-based drugs have been used primarily to treat ulcers caused by Helicobacter pylori and other gastrointestinal ailments. Combined with antibiotics, these drugs also possess synergistic activity, making them ideal for multiple therapy regimens and overcoming bacterial resistance. Compounds based on bismuth have a low cost, are safe for human use, and some of them are also effective against tumoral cells, leishmaniasis, fungi, and viruses. However, these compounds have limited bioavailability in physiological environments. As a result, there is a growing interest in developing new bismuth compounds and approaches to overcome this challenge. Considering the beneficial properties of bismuth and the importance of discovering new drugs, this review focused on the last decade's updates involving bismuth compounds, especially those with potent activity and low toxicity, desirable characteristics for developing new drugs. In addition, bismuth-based compounds with dual activity were also highlighted, as well as their modes of action and structure-activity relationship, among other relevant discoveries. In this way, we hope this review provides a fertile ground for rationalizing new bismuth-based drugs.

Antibacterial performance of heterocyclic organobismuth (III) complexes based on bidentate C,O‐coordinating ligands: Synergism of ligand identity and coordination number

A series of heterocyclic organobismuth (III) complexes based on bidentate C,O‐coordinating ligands were designed and synthesized as antimicrobials. Antibacterial assays showed that complexes of this type are more effective for Gram‐positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecalis) than Gram‐negative ones (Escherichia coli and Pseudomonas aeruginosa). Their activities are especially relevant to the synergism of lipophilicity, geometry, and stability, which depends on both the identity of coordinating ligands and the coordination number at the bismuth center. By comparison, the hypervalent 14‐Bi‐6 species diarylbismuth nitrate (8) was found to exhibit the most potent inhibitory effect, together with a high degree of selectivity, which gives an IC50(LO2)/MIC(Staphylococcus aureus) ratio of up to 23.08. Time–kill analysis demonstrated that complex 8 is bacteriostatic at low concentrations while displaying significant bactericidal activity at high doses. The results of drug resistance experiments suggested that complex 8 can inhibit the formation of bacterial biofilm and consequently delay or prevent the development of drug resistance. Furthermore, complex 8 also showed high inhibition efficiency against several drug‐resistant Staphylococcus aureus, and the MIC values are within the range of 0.39–1.56 μM, thus indicating the lack of cross‐resistance between this organometallic compound and commonly used antibiotics.

Diverse Pathways of Engineered Nanoparticle-Induced NLRP3 Inflammasome Activation

With the rapid development of engineered nanomaterials (ENMs) in biomedical applications, their biocompatibility and cytotoxicity need to be evaluated properly. Recently, it has been demonstrated that inflammasome activation may be a vital contributing factor for the development of biological responses induced by ENMs. Among the inflammasome family, NLRP3 inflammasome has received the most attention because it directly interacts with ENMs to cause the inflammatory effects. However, the pathways that link ENMs to NLRP3 inflammasome have not been thoroughly summarized. Thus, we reviewed recent findings on the role of major ENMs properties in modulating NLRP3 inflammasome activation, both in vitro and in vivo, to provide a better understanding of the underlying mechanisms. In addition, the interactions between ENMs and NLRP3 inflammasome activation are summarized, which may advance our understanding of safer designs of nanomaterials and ENM-induced adverse health effects.

Building a Green, Robust, and Efficient Bi-MOF Heterogeneous Catalyst for the Strecker Reaction of Ketones

In this work, we present the new [Bi₁₄(μ₃-O)₉(μ₄-O)₂(μ_3–OH)₅(3,5-DSB)₅(H₂O)₃]·7H₂O, BiPF-4 (bismuth polymeric framework—4) MOF, its microwave hydrothermal synthesis, as well as its behavior as a heterogeneous catalyst in the multicomponent organic Strecker reaction. The BiPF-4 material shows a three-dimensional (3D) framework formed by peculiar inorganic oxo-hydroxo-bismutate layers connected among them through the 3,5-dsb (3,5-disulfobenzoic acid) linker. These two-dimensional (2D) layers, built by junctions of Bi7 polyhedra SBU, provide the material of many Lewis acid catalytic sites because of the mixing in the metal coordination number. BiPF-4 is a highly robust, green, and stable material that demonstrates an excellent heterogeneous catalytic activity in the multicomponent Strecker reaction of ketones carried out in one-pot synthesis, bringing a reliable platform of novel green materials based on nontoxic and abundant metal sources such as bismuth.

In this work, we present the new [Bi₁₄(μ₃-O)₉(μ₄-O)₂(μ₃₋OH)₅(3,5-DSB)₅(H₂O)₃]·7H₂O, BiPF-4 (bismuth polymeric framework—4) MOF, its microwave hydrothermal synthesis, as well as its behavior as a heterogeneous catalyst in the multicomponent organic Strecker reaction.

Aryl bismuth phosphinates [BiAr2(O(O)PRR’)]: structure-activity relationships for antibacterial activity and cytotoxicity

To study and evaluate the structure-activity relationships in di-aryl bismuth phosphinates on antibacterial activity and cytotoxicity a series of complexes containing ortho-methoxyphenyl, meta-methoxyphenyl, meta-tolyl and para-tolyl aryl groups; [Bi(o-MeOPh)2(O(O)P(H)Ph)]n 1,...

Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles

Bismuth as a relatively non-toxic and inexpensive metal with exceptional properties has numerous biomedical applications. Bismuth-based compounds are used extensively as medicines for the treatment of gastrointestinal disorders including dyspepsia, gastric ulcers and H. pylori infections. Recently, its medicinal application was further extended to potential treatments of viral infection, multidrug resistant microbial infections, cancer and also imaging, drug delivery and biosensing. In this review we have highlighted the unique chemistry and biological chemistry of bismuth-209 as a prelude to sections covering the unique antibacterial activity of bismuth including a description of research undertaken to date to elucidate key molecular mechanisms of action against H. pylori, the development of novel compounds to treat infection from microbes beyond H. pylori and the significant role bismuth compounds can play as resistance breakers. Furthermore we have provided an account of the potential therapeutic application of bismuth-213 in targeted alpha therapy as well as a summary of the biomedical applications of bismuth-based nanoparticles and composites. Ultimately this review aims to provide the state of the art, highlight the untapped biomedical potential of bismuth and encourage original contributions to this exciting and important field.

Bismuth(III) Thiophosphinates: Understanding How a Small Atomic Change Influences Antibacterial Activity and Mammalian Cell Viability

Diphenylphosphinothioic acid (HSP(=O)Ph2) and diphenylphosphinodithioic acid (HSP(=S)Ph2) have been used to synthesise four BiIII complexes: 1 [Bi(SP(=O)Ph2)3], 2 [BiPh(SP(=O)Ph2)2], 3 [BiPh2(SP(=O)Ph2)], and 4 [Bi(SP(=S)Ph2)3], using BiPh3 and [Bi(OtBu)3] as bismuth sources. The complexes have been characterised by NMR spectroscopy, mass spectrometry, infrared spectroscopy, powder X-ray diffraction, and singe crystal X-ray crystallography (2–4). Biological studies indicated that despite complexes 2 and 3 reducing mammalian cell viability, their antibacterial activity provides a good degree of selectivity towards both Gram positive and Gram negative bacterial strains. The minimum inhibitory concentrations for complexes 2 and 3 are in the range of 0.52–5.5µM towards the bacteria tested. Homoleptic complexes 1 and 4 were generally less active towards both bacterial and mammalian cells.